Hwail Pharmaceutical Co.Ltd (061250) - Net Assets
Based on the latest financial reports, Hwail Pharmaceutical Co.Ltd (061250) has net assets worth ₩207.86 Billion KRW (≈ $140.86 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩213.14 Billion ≈ $144.45 Million USD) and total liabilities (₩5.29 Billion ≈ $3.58 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 061250 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩207.86 Billion |
| % of Total Assets | 97.52% |
| Annual Growth Rate | 8.61% |
| 5-Year Change | 29.68% |
| 10-Year Change | 105.59% |
| Growth Volatility | 9.94 |
Hwail Pharmaceutical Co.Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Hwail Pharmaceutical Co.Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Hwail Pharmaceutical Co.Ltd (061250) total assets for the complete picture of this company's asset base.
Annual Net Assets for Hwail Pharmaceutical Co.Ltd (2011–2024)
The table below shows the annual net assets of Hwail Pharmaceutical Co.Ltd from 2011 to 2024. For live valuation and market cap data, see 061250 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩203.42 Billion ≈ $137.85 Million |
+16.60% |
| 2023-12-31 | ₩174.45 Billion ≈ $118.22 Million |
-0.64% |
| 2022-12-31 | ₩175.57 Billion ≈ $118.98 Million |
-3.35% |
| 2021-12-31 | ₩181.66 Billion ≈ $123.11 Million |
+15.81% |
| 2020-12-31 | ₩156.86 Billion ≈ $106.30 Million |
+31.34% |
| 2019-12-31 | ₩119.43 Billion ≈ $80.94 Million |
+17.96% |
| 2018-12-31 | ₩101.25 Billion ≈ $68.61 Million |
+3.12% |
| 2017-12-31 | ₩98.18 Billion ≈ $66.53 Million |
-1.68% |
| 2016-12-31 | ₩99.86 Billion ≈ $67.67 Million |
+0.93% |
| 2015-12-31 | ₩98.94 Billion ≈ $67.05 Million |
+11.09% |
| 2014-12-31 | ₩89.07 Billion ≈ $60.36 Million |
+3.20% |
| 2013-12-31 | ₩86.31 Billion ≈ $58.49 Million |
+4.97% |
| 2012-12-31 | ₩82.22 Billion ≈ $55.72 Million |
+18.33% |
| 2011-12-31 | ₩69.49 Billion ≈ $47.09 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hwail Pharmaceutical Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 8385305911000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩83.85 Billion | 41.22% |
| Common Stock | ₩42.20 Billion | 20.74% |
| Other Components | ₩77.37 Billion | 38.03% |
| Total Equity | ₩203.42 Billion | 100.00% |
Hwail Pharmaceutical Co.Ltd Competitors by Market Cap
The table below lists competitors of Hwail Pharmaceutical Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Metair
JSE:MTA
|
$53.64 Million |
|
Kronos Bio Inc
NASDAQ:KRON
|
$53.65 Million |
|
Top High Image
TWO:3284
|
$53.66 Million |
|
Allegiant Gold Ltd
V:AUAU
|
$53.67 Million |
|
Instil Bio Inc.
NASDAQ:TIL
|
$53.58 Million |
|
Airmate Cayman International Co Ltd
TW:1626
|
$53.57 Million |
|
Botnia Gold AB (publ)
ST:BOTX
|
$53.57 Million |
|
Kingston Resources Ltd
AU:KSN
|
$53.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hwail Pharmaceutical Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 174,453,635,220 to 203,415,490,920, a change of 28,961,855,700 (16.6%).
- Net income of 6,481,446,230 contributed positively to equity growth.
- Share repurchases of 22,999,997,030 reduced equity.
- New share issuances of 22,999,997,030 increased equity.
- Other factors increased equity by 22,480,409,470.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩6.48 Billion | +3.19% |
| Share Repurchases | ₩23.00 Billion | -11.31% |
| Share Issuances | ₩23.00 Billion | +11.31% |
| Other Changes | ₩22.48 Billion | +11.05% |
| Total Change | ₩- | 16.60% |
Book Value vs Market Value Analysis
This analysis compares Hwail Pharmaceutical Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.37x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩2461.49 | ₩943.00 | x |
| 2017-12-31 | ₩2420.04 | ₩943.00 | x |
| 2018-12-31 | ₩2495.62 | ₩943.00 | x |
| 2019-12-31 | ₩2426.67 | ₩943.00 | x |
| 2020-12-31 | ₩2616.85 | ₩943.00 | x |
| 2021-12-31 | ₩2767.76 | ₩943.00 | x |
| 2022-12-31 | ₩2638.90 | ₩943.00 | x |
| 2023-12-31 | ₩2717.65 | ₩943.00 | x |
| 2024-12-31 | ₩2525.81 | ₩943.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hwail Pharmaceutical Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.19%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.41%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 1.06x
- Recent ROE (3.19%) is below the historical average (3.56%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 6.74% | 6.00% | 0.79x | 1.42x | ₩-2.26 Billion |
| 2012 | 6.15% | 5.51% | 0.81x | 1.38x | ₩-3.16 Billion |
| 2013 | 4.88% | 4.47% | 0.77x | 1.43x | ₩-4.42 Billion |
| 2014 | 4.64% | 4.30% | 0.78x | 1.38x | ₩-4.78 Billion |
| 2015 | 5.51% | 5.14% | 0.76x | 1.42x | ₩-4.44 Billion |
| 2016 | 6.39% | 5.72% | 0.87x | 1.29x | ₩-3.60 Billion |
| 2017 | 2.71% | 2.60% | 0.83x | 1.26x | ₩-7.15 Billion |
| 2018 | 5.01% | 4.97% | 0.83x | 1.22x | ₩-5.05 Billion |
| 2019 | 2.67% | 2.94% | 0.78x | 1.17x | ₩-8.75 Billion |
| 2020 | 1.79% | 2.27% | 0.73x | 1.08x | ₩-12.88 Billion |
| 2021 | 1.56% | 2.66% | 0.55x | 1.07x | ₩-15.32 Billion |
| 2022 | -3.60% | -4.79% | 0.71x | 1.06x | ₩-23.88 Billion |
| 2023 | 2.21% | 3.15% | 0.66x | 1.07x | ₩-13.58 Billion |
| 2024 | 3.19% | 5.41% | 0.56x | 1.06x | ₩-13.86 Billion |
Industry Comparison
This section compares Hwail Pharmaceutical Co.Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $401,390,357,055
- Average return on equity (ROE) among peers: 0.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hwail Pharmaceutical Co.Ltd (061250) | ₩207.86 Billion | 6.74% | 0.03x | $53.61 Million |
| Dongwha Pharm.Co.Ltd (000020) | $252.93 Billion | 10.38% | 0.28x | $113.83 Million |
| Yuhan Corp. (000100) | $407.93 Billion | 10.79% | 0.55x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 2.42% | 0.28x | $59.61 Million |
| Yuyu Pharma (000220) | $69.50 Billion | 3.97% | 0.28x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $117.04 Billion | 1.10% | 0.32x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $169.10 Billion | -60.53% | 4.10x | $76.14 Million |
| Samil Pharm (000520) | $127.83 Billion | 1.30% | 1.90x | $127.90 Million |
| Donga Socio Holdings (000640) | $875.86 Billion | 17.02% | 0.60x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About Hwail Pharmaceutical Co.Ltd
Hwail Pharmaceutical Co.,Ltd. develops pharmaceutical raw materials in South Korea. It provides raw drug products, finished drug products, and functional health food raw material business. The company was founded in 1974 and is headquartered in Seongnam-si, South Korea.